Table 3 Associations between circulating biomarkers of inflammation and CRC-specific mortality according to time of follow-up since blood draw, overall (n = 302) and among those with CRP ≤ 10 mg/L (n = 244).

From: Association between post-treatment circulating biomarkers of inflammation and survival among stage II–III colorectal cancer patients

Markersa

HR (95% CI)b

 

<1 year

1–3 years

>3 years

All (n = 302)

  No. of deaths/total

17/302

18/280

18/258

   CRP (mg/L)

1.75 (1.2–2.56)

1.31 (0.9–1.93)

1.22 (0.83–1.79)

   IL-6 (pg/mL)

5.01 (2.92–8.59)

2.66 (1.52–4.66)

2.03 (1.1–3.72)

   MCP-1 (pg/mL)

3.78 (1.41–10.08)

1.14 (0.29–4.49)

1.17 (0.31–4.45)

   Adiponectin (μg/mL)

3.16 (1.27–7.86)

1.83 (0.77–4.35)

0.57 (0.23–1.39) 

   Leptin (ng/mL)

0.44 (0.29–0.68)

1.04 (0.71–1.53)

0.93 (0.63–1.36)

CRP ≤ 10 mg/L (n = 244)

  N deaths/Total

8/244

12/232

14/216

   CRP (mg/L)

0.65 (0.34–1.25)

0.97 (0.53–1.77)

0.99 (0.57–1.72)

   IL-6 (pg/mL)

6.23 (2.97–13.04)

3.99 (1.76–9.09)

1.74 (0.69–4.34)

   MCP-1 (pg/mL)

5.53 (0.9–34.16)

1.86 (0.32–10.64)

0.54 (0.09–3.09)

   Adiponectin (μg/mL)

5.45 (1.5–19.83)

2.29 (0.79–6.65)

0.84 (0.31–2.28)

   Leptin (ng/mL)

0.45 (0.23–0.86)

0.96 (0.58–1.6)

0.9 (0.57–1.44)

  1. CRC colorectal cancer, CRP C-reactive protein, IL-6 interleukin-6, MCP-1 monocyte chemoattractive protein-1, HR hazard ratio, CI confidence interval.
  2. aNatural log-transformed: HRs per unit increase in natural logarithmic biomarker.
  3. bInterval-specific HRs (95% CI) were calculated using extended Cox models with time-varying coefficient to estimate the associations between the logarithmic biomarker and CRC-specific mortality within 1, 1–3, and >3 years after the blood draw. HRs were stratified by stage at diagnosis and adjusted for age at blood draw, sex, pre-diagnostic body mass index (BMI), smoking status at baseline, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) at baseline, plasma storage time, and years between diagnosis and blood draw.